A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
Hagen P, Sidana S, Parker T, Walker B, Hoering A, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Ailawadhi S, Orlowski R. A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. Journal Of Clinical Oncology 2024, 42: tps7575-tps7575. DOI: 10.1200/jco.2024.42.16_suppl.tps7575.Peer-Reviewed Original ResearchAutologous stem cell transplantationProgression free survivalStem cell transplantationOverall survivalCell transplantationASCT armNext generation flow cytometryLight chain (AL) amyloidosisDaratumumab to bortezomibDiagnosed AL amyloidosisTwo-sided significance levelPlasma cell malignancyShort follow-upDaratumumab maintenanceMRD negativityFree survivalInduction therapyIntergroup trialMultiple myelomaAL amyloidosisHematologic responseRenal responseRandomized studyCell malignancyFollow-up